Background Combinations of drug treatments based on bortezomib or lenalidomide plus
steroids have resulted in very high response rates in multiple myeloma. However, most …

Purpose Despite advancements, prognosis for patients with relapsed/refractory multiple
myeloma (MM) is poor, and novel therapies are needed. Panobinostat is a potent …

Oral panobinostat (Farydak®), a potent nonselective histone deacetylase inhibitor, is
approved in several countries for use in combination with bortezomib and dexamethasone …

Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of
multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein …

Background Panobinostat (a pan histone deacetylase inhibitor) is approved in combination
with bortezomib and dexamethasone for patients with relapsed multiple myeloma who have …

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical
studies has synergistic anti-myeloma activity when combined with bortezomib and …

Phase 3 studies combining histone deacetylase inhibitors with bortezomib were hampered
by gastrointestinal (GI) intolerance, which was not observed when combined with …

Outcomes for patients with multiple myeloma (MM) have improved significantly over the past
decade. Despite these advances, MM remains incurable and an unmet medical need …

Panobinostat is an oral pan-deacetylase inhibitor that synergizes with bortezomib to inhibit
both the aggresome and proteasome pathways in preclinical studies. PANORAMA 2 is a …

Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through
epigenetic mechanisms and inhibits protein degradation. It was recently approved by the …